20th Annual Needham Virtual Healthcare Conference
Receive updates straight into your inbox
Matinas BioPharma is a clinical-stage biopharmaceutical company focused on development of its lead product candidate, LYPDISO, for the treatment of cardiovascular and metabolic conditions. LYPDISO is a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA, under development for hypertriglyceridemia, that was specifically designed to overcome the shortcomings seen from other agents in the omega-3 class. Company leadership has a deep history and knowledge of cardiovascular drug development and is supported by a world-class team of scientific advisors. The company will soon begin enrolling LYPDISO in a confirmatory head-to-head PD study vs Vascepa, after having shown superiority versus Vascepa® (icosapent ethyl) in reducing serum triglycerides, Total- and Non-HDL-Cholesterol, apolipoprotein CIII and PCSK9 levels in a previous study, with data expected in the fourth quarter of 2020.
In addition, the Company is developing MAT2203, an oral, encochleated formulation of amphotericin B, to treat serious invasive fungal infections. The drug is based on Matinas’ proprietary lipid nano-crystal (LNC) platform technology which can help solve complex challenges relating to the safe and effective delivery of potent medicines, potentially making them more targeted, less toxic and orally bioavailable.
Matinas BioPharma Holdings, Inc.
1545 Route 206 South
Bedminster, NJ 07921
T: (443) 213-0505
VStock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598
T: (212) 828-8436
F: (646) 536-3179